IP Library Granted Patent US 11,874,280
Granted Patent B2
US 11,874,280 · App. 16/982,341 · Granted Jan 16, 2024

Use of divalent metals for enhancement of fluorescent signals

Inventors: Melissa Jackson (New York, NY); Christopher Boyce (New York, NY); Eriko Matsui (New York, NY); Michael Vanbrunt (Covington, WA); Sharat Singh (Rancho Santa Fe, CA); Tracy Matray (Snohomish, WA)
Assignee: Sony Group Corporation
G01N33/582G01N33/533
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,874,280
App. No.
16/982,341
Granted
Jan 16, 2024
Kind
B2
Abstract

Compositions comprising fluorescent or colored dyes and methods of using the same in combination with divalent metal salts to analyze samples are disclosed.

Claims (131)

1. A method for forming a covalent conjugate of a polymeric dye and a targeting moiety, the method comprising preparing a mixture comprising the polymeric dye, the targeting moiety, and a magnesium salt, and allowing the mixture to age for a time and at a temperature sufficient to form the covalent conjugate, wherein:

a) the polymeric dye comprises:

i) two or more fluorescent or colored moieties;

ii) at least one negatively charged phosphate group; and

iii) a reactive group Q capable of forming a covalent bond with a complementary reactive group Q′ on the targeting moiety,

wherein each of the two or more fluorescent or colored moieties are joined to an adjacent fluorescent or colored moiety via a linker comprising the at least one negatively charged phosphate group; and

b) the targeting moiety has affinity for a target analyte and comprises the complementary reactive group Q′.

2. A method for detecting a target analyte, the method comprising:

a) associating a covalent conjugate with the target analyte to form an analyte-targeting moiety complex in the presence of a magnesium salt, the covalent conjugate comprising:

i) a targeting moiety that has affinity for the target analyte and comprises a covalent bond to a polymeric dye;

ii) the polymeric dye comprising:

A) two or more fluorescent or colored moieties;

B) at least one negatively charged phosphate group; and

C) a covalent bond to the targeting moiety,

wherein each of the two or more fluorescent or colored moieties are joined to an adjacent fluorescent or colored moiety via a linker comprising the at least one negatively charged phosphate group; and

b) detecting a fluorescent or colored signal from the analyte-targeting moiety complex.

3. The method of claim 2 , further comprising treating the analyte-targeting moiety complex with a wash solution comprising a magnesium salt.

4. A method for detecting a target analyte, the method comprising:

a) associating a covalent conjugate with the target analyte to form an analyte-targeting moiety complex, the covalent conjugate comprising:

i) a targeting moiety that has affinity for the target analyte and comprises a covalent bond to a polymeric dye; and

ii) the polymeric dye comprising:

A) two or more fluorescent or colored moieties;

B) at least one negatively charged phosphate group; and

C) a covalent bond to the targeting moiety,

wherein each of the two or more fluorescent or colored moieties are joined to an adjacent fluorescent or colored moiety via a linker comprising the at least one negatively charged phosphate group;

b) treating:

i) the covalent conjugate and the target analyte with a magnesium salt during the associating the covalent conjugate and the target analyte; and/or

ii) the analyte-targeting moiety complex with a wash solution comprising a magnesium salt after the associating the covalent conjugate and the target analyte; and

c) detecting a fluorescent or colored signal from the analyte-targeting moiety complex.

5. The method of claim 2 , further comprising substantially removing all of the magnesium salt from the analyte-targeting moiety complex before detecting the fluorescent or colored signal.

6. The method of claim 5 , wherein the magnesium salt is removed from a buffer comprising the analyte-targeting moiety complex.

7. The method of claim 2 , further comprising forming the covalent conjugate.

8. The method of claim 7 , wherein the polymeric dye and a magnesium salt have been admixed to form a composition comprising the polymeric dye and the magnesium salt prior to forming the covalent conjugate.

9. The method of claim 8 , further comprising aging the composition comprising the polymeric dye and the magnesium salt prior to forming the covalent conjugate.

10. The method of claim 7 , wherein magnesium salts are substantially absent while forming the covalent conjugate.

11. A composition comprising a covalent conjugate and a magnesium salt, the covalent conjugate comprising:

i) a targeting moiety comprising a covalent bond to a polymeric dye;

ii) the polymeric dye comprising:

a) two or more fluorescent or colored moieties;

b) at least one negatively charged phosphate group; and

c) a covalent bond to the targeting moiety,

wherein each of the two or more fluorescent or colored moieties are joined to an adjacent fluorescent or colored moiety via a linker comprising the at least one negatively charged phosphate group.

12. The method of claim 2 , wherein the magnesium salt is magnesium chloride.

13. The method of claim 2 , further comprising purifying the covalent conjugate.

14. The method or composition of claim 13 , wherein purifying comprises substantially removing all of the magnesium salt from the covalent conjugate.

15. The method of claim 2 , wherein the covalent conjugate has a fluorescent extinction coefficient at least 1.1 times higher than a corresponding conjugate prepared in the absence of the magnesium salt.

16. The method of claim 2 , wherein the targeting moiety is an antibody.

17. The method of claim 2 , wherein the polymeric dye has the following structure (I):

or a stereoisomer, salt or tautomer thereof, wherein:

M is, at each occurrence, independently a moiety comprising the fluorescent or colored moiety;

L 1 is at each occurrence, independently either: i) an optional alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, heteroalkynylene or heteroatomic linker; or ii) a linker comprising a functional group capable of formation by reaction of two complementary reactive groups;

L 2 and L 3 are, at each occurrence, independently an optional alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, heteroalkynylene or heteroatomic linker;

L 4 is, at each occurrence, independently an alkylene or alkylene oxide linker;

R 1 is, at each occurrence, independently H, alkyl or alkoxy;

R 2 and R 3 are each independently H, OH, SH, alkyl, alkoxy, alkylether, heteroalkyl, —OP(═R a )(R b )R c , Q, or a protected form thereof, or L′;

R 4 is, at each occurrence, independently OH, SH, O − , S − , OR d or SR d ;

R 5 is, at each occurrence, independently oxo, thioxo or absent;

R a is O or S;

R b is OH, SH, O − , S − , OR d or SR d ;

R c is OH, SH, O − , S − , OR d , OL′, SR d , alkyl, alkoxy, heteroalkyl, heteroalkoxy, alkylether, alkoxyalkylether, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkyl ether;

R d is a counter ion;

L′ is, at each occurrence, independently a linker comprising a covalent bond to Q, a linker comprising a covalent bond to the targeting moiety, a linker comprising a covalent bond to an analyte molecule, a linker comprising a covalent bond to a solid support, a linker comprising a covalent bond to a solid support residue, a linker comprising a covalent bond to a nucleoside or a linker comprising a covalent bond to a further compound of structure (I);

m is, at each occurrence, independently an integer of zero or greater, provided that at least one occurrence of m is an integer of one or greater, such that the compound includes at least one L 4 ; and

n is an integer of one or greater.

18. The method claim 17 , wherein the polymeric dye has the following structure (IA):

wherein z is an integer from 2 to 100.

19. The method of claim 18 , wherein the compound has the following structure (TB):

wherein:

x 1 , x 2 , x 3 and x 4 are, at each occurrence, independently an integer from 0 to 6; and

z is an integer from 2 to 100.

20. The method of claim 17 , wherein L′ comprises an alkylene oxide or phosphodiester moiety, or combinations thereof.

21. The method of claim 17 , wherein Q comprises a sulfhydryl, disulfide, activated ester, isothiocyanate, azide, alkyne, alkene, diene, dienophile, acid halide, sulfonyl halide, phosphine, α-haloamide, biotin, amino or maleimide functional group.

22. The method of claim 17 , wherein M is, at each occurrence, independently a dimethylaminostilbene, quinacridone, fluorophenyl-dimethyl-BODIPY, bis-fluorophenyl-BODIPY, acridine, terrylene, sexiphenyl, porphyrin, benzopyrene, (fluorophenyl-dimethyl-difluorobora-diaza-indacene)phenyl, (bis-fluorophenyl-difluorobora-diaza-indacene)phenyl, quaterphenyl, bi-benzothiazole, ter-benzothiazole, bi-naphthyl, bi-anthracyl, squaraine, squarylium, 9, 10-ethynylanthracene or ter-naphthyl moiety.

23. The method of claim 17 , wherein the polymeric dye has one of the following structures:

wherein:

z is an integer from 3 to 6,

m is an integer from 2 to 5, and

n is an integer from 1 to 10;

wherein:

wherein:

wherein:

wherein:

wherein A is an antibody, and

wherein:

wherein:

wherein m″ is 4 or 10, and

wherein:

wherein m″ is 4 or 10 and A is an antibody, and

wherein:

wherein m″ is 4 or 10, and

wherein:

wherein m″ is 4 or 10, and

wherein:

wherein m″ is 4 or 10, and

wherein:

wherein:

wherein:

wherein:

wherein:

wherein:

wherein m″ is 4 or 10, and

wherein:

wherein:

wherein:

wherein:

wherein:

wherein:

wherein:

wherein:

wherein:

wherein:

wherein:

wherein:

wherein:

wherein:

wherein:

wherein:

wherein:

wherein:

wherein:

wherein:

wherein:

wherein:

wherein:

wherein A is an antibody;

wherein:

wherein A is an antibody; or

wherein n is 23, wherein:

F, F′ and F″ have the following structures, respectively:

and

dT has the following structure:

Assignments (3)
CHANGE OF NAME Recorded May 16, 2023
From: SONY CORPORATION
To: SONY GROUP CORPORATION
Reel/Frame 063664/0744 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2021
From: JACKSON, MELISSA; BOYCE, CHRISTOPHER; MATSUI, ERIKO; VANBRUNT, MICHAEL; SINGH, SHARAT; MATRAY, TRACY
To: SONY CORPORATION OF AMERICA; SONY CORPORATION
Reel/Frame 055201/0443 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2020
From: SONY CORPORATION OF AMERICA
To: SONY CORPORATION
Reel/Frame 054751/0070 →
Continuity (2)
Provisional Application 62645121 · Mar 19, 2018
Related Publication 20210109104A1 · Apr 15, 2021
Cited By (15)
US 12,194,104 US 12,270,812 US 12,275,851 US 12,290,571 US 12,319,817 US 12,359,071 US 12,391,833 US 12,461,106 US 12,473,433 US 12,539,334 US 12,560,612 US 12,577,403 US 12,578,342 US 12,606,588 US 12,629,425